This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer
by Zacks Equity Research
This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.
AZNNegative Net Change MRKPositive Net Change ARCTNegative Net Change FULCNegative Net Change
biotechs medical pharmaceuticals
Medicare Releases Negotiated Prices on 10 Expensive Drugs
by Sundeep Ganoria
Following negotiations between Medicare and participating drug companies, some of the world's biggest medicines will see price cuts of 38-79%. These lowered prices will be going into effect in 2026.
AZNNegative Net Change NVSNegative Net Change BMYNegative Net Change JNJNegative Net Change MRKPositive Net Change AMGNNegative Net Change
biotechs medical pharmaceuticals vaccines
Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.
ILMNPositive Net Change KODPositive Net Change FULCNegative Net Change
biotechs earnings
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
by Zacks Equity Research
Axsome's (AXSM) depression drug, Auvelity, is driving the company's top line. The acquisition of Sunosi from Jazz diversifies its commercial opportunity. Stiff competition in the target market is a woe.
JAZZNegative Net Change ACADNegative Net Change AXSMPositive Net Change
biotechs
Vertex (VRTX) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
Vertex's (VRTX) CF sales are expected to remain strong despite a slight slowdown in the growth rate. Casgevy and suzetrigine (if approved) are set to provide the necessary diversification from the CF franchise.
VRTXNegative Net Change MRNAPositive Net Change CRSPNegative Net Change
biotechs
AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.
AZNNegative Net Change MRKPositive Net Change IMTXNegative Net Change TRDAPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up
by Zacks Equity Research
Lexicon (LXRX) announces a portfolio reprioritization plan to focus on reducing operational expenses and driving the growth of the commercial portfolio. Shares rise.
ILMNPositive Net Change LXRXNegative Net Change FULCNegative Net Change TRDAPositive Net Change
biotechs
Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath
by Zacks Equity Research
The FDA approves Ascendis' (ASND) Yorvipath (palopegteriparatide) as the first and only treatment for hypoparathyroidism in adult patients. Shares rise.
ILMNPositive Net Change ASNDNegative Net Change FULCNegative Net Change TRDAPositive Net Change
biotechs
Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY
by Zacks Equity Research
A $75 million performance-based and program-based milestone payment has been triggered in favor of Evotec (EVO) under its strategic collaboration with Bristol Myers for molecular glue degraders.
BMYNegative Net Change PFENegative Net Change EVONegative Net Change TRDAPositive Net Change
biotechs medical pharmaceuticals
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
by Zacks Equity Research
Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.
ABBVNegative Net Change IMTXNegative Net Change TRDAPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow
by Zacks Equity Research
FATE reports a lower-than-expected loss on higher revenues and lower operating expenses in the second quarter of 2024.
FATEPositive Net Change KRYSNegative Net Change TRDAPositive Net Change
biotechnology biotechs cell-therapy earnings medical
Here's How to Play Novo Nordisk (NVO) After Q2 Earnings Miss
by Ahan Chakraborty
Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.
PFENegative Net Change NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer (PFE) Touts RSV Jab Benefit in Immunocompromised Adults
by Zacks Equity Research
Results from a late-stage study show that Pfizer's (PFE) RSV vaccine generated strong neutralizing responses in immunocompromised adults after receiving a single dose.
GSKNegative Net Change PFENegative Net Change MRNAPositive Net Change
biotechs medical messenger-rna vaccines
Here's Why You Should Invest in BioMarin (BMRN) Stock Now
by Zacks Equity Research
Here, we are discussing some reasons why investing in BioMarin (BMRN) stock now may turn out to be a prudent move.
BMRNNegative Net Change FULCNegative Net Change IMTXNegative Net Change TRDAPositive Net Change
biotechs
Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results
by Zacks Equity Research
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.
BMYNegative Net Change EXELNegative Net Change KRYSNegative Net Change TRDAPositive Net Change
biotechnology biotechs pharmaceuticals
Bristol Myers (BMY) Gains 16% in a Month: Should You Buy or Wait?
by Ekta Bagri
Bristol Myers' (BMY) impressive second-quarter results propelled the stock in the past month. However, we advise investors not to be over-optimistic at this point and look before they leap.
BMYNegative Net Change PFENegative Net Change GILDNegative Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B
by Zacks Equity Research
Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.
MRKPositive Net Change ELANNegative Net Change FULCNegative Net Change TRDAPositive Net Change
biotechs medical pharmaceuticals
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
by Zacks Equity Research
Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.
PCRXPositive Net Change FULCNegative Net Change IMTXNegative Net Change TRDAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View
by Zacks Equity Research
Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.
INSMNegative Net Change FULCNegative Net Change IMTXNegative Net Change TRDAPositive Net Change
biotechs earnings medical
Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.
REGNNegative Net Change NTLANegative Net Change FULCNegative Net Change TRDAPositive Net Change
biotechs earnings
Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook
by Zacks Equity Research
Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.
SNYPositive Net Change NVAXPositive Net Change FULCNegative Net Change TRDAPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
by Zacks Equity Research
Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.
FOLDPositive Net Change ANIXPositive Net Change AKRONegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
by Zacks Equity Research
Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
NBIXPositive Net Change XENENegative Net Change AKRONegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
by Zacks Equity Research
Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.
GSKNegative Net Change GILDNegative Net Change ANIXPositive Net Change TRDAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
by Zacks Equity Research
Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.
IOVANegative Net Change FULCNegative Net Change IMTXNegative Net Change TRDAPositive Net Change
biotechs cell-therapy earnings medical